Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2024 (Event Date)
Reporting Period: Specific event reporting; not a periodic financial report.
On December 13, 2024, the Company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, a Cayman Islands exempt limited partnership (the "Investor").
Key Financial Metrics and Transaction Terms
This filing details a financing facility rather than historical financial performance. Key terms include:
- Commitment Amount: Up to $10 million in aggregate common shares.
- Share Price: 97% of the lowest daily Volume Weighted Average Price (VWAP) during the three consecutive trading days commencing on the date of the Advance Notice.
- Maximum Advance Amount: The lower of (i) 100% of the average Daily Traded Amount over the preceding five trading days, or (ii) $1 million per Advance Notice.
- Term: Automatically terminates on the earliest of January 1, 2027, or the date the full Commitment Amount is purchased.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Fees
The Company incurred immediate and future costs associated with the SEPA:
- Structuring Fee: $25,000 paid to the Investor upon execution.
- Commitment Fee: 2.50% of the Commitment Amount ($250,000 total).
- Upfront Payment: 25% of the Commitment Fee ($62,500) payable in cash within three business days of the Effective Date.
- Deferred Fee: 75% of the Commitment Fee ($187,500) payable in three equal quarterly installments beginning three months after the Effective Date. These may be paid in cash or common shares at the Company's option.
The filing does not provide historical revenue, profit, cash flow, or debt figures for comparison.
Outlook, Risks, and Management Commentary
- Discretionary Sales: The Company has the right, but not the obligation, to sell shares. Sales timing and amounts are at the Company's discretion based on market conditions and funding needs.
- Minimum Price: The Company may establish a minimum acceptable price in each Advance Notice below which it is not obligated to sell.
- Termination Rights: The Company may terminate the SEPA at no cost upon five business days' prior written notice, provided no outstanding Advance Notices exist.
- Regulatory Status: Shares are sold pursuant to Section 4(a)(2) and Rule 506 of Regulation D exemptions. A registration statement for resale must be declared effective by the SEC before sales can occur.
Investor Verification Checklist
- Verify the effectiveness of the Registration Statement required for the resale of shares under the SEPA.
- Confirm the cash impact of the $62,500 upfront commitment fee payment.
- Monitor the Company's decision on whether to pay the deferred fees in cash or shares, which could impact share count and dilution.
- Review the Company's historical trading volume to assess the practical limit of the $1 million or 100% Daily Traded Amount cap on advances.
- Check for any subsequent filings regarding the actual issuance of shares under this agreement.